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Drug combination therapy is a key strategy to improve treatment efficacy and survival of cancer patients. In this study the effects of
combining 2-methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140), a microtubule disruptor, with 2-deoxy-D-glucose (2DG) were
assessed in MCF-7 (breast) and LNCaP (prostate) xenograft models in vivo. In mice bearing MCF-7 xenografts, daily p.o.
administration of STX140 (5mgkg
 1) resulted in a 46% (Po0.05) reduction of tumour volume. However, the combination of
STX140 (5mgkg
 1 p.o.) and 2DG (2gkg
 1 i.p.) reduced tumour volume by 76% (Po0.001). 2-Methoxyoestradiol-3,17-O,O-bis-
sulphamate also reduced tumour vessel density. 2-Deoxy-D-glucose alone had no significant effect on tumour volume or vessel
density. A similar benefit of the combination treatment was observed in the LNCaP prostate xenograft model. In vitro the degree of
inhibition of cell proliferation by STX140 was unaffected by oxygen concentrations. In contrast, the inhibition of proliferation by 2DG
was enhanced under hypoxia by 20 and 25% in MCF-7 and LNCaP cells, respectively. The combination of STX140 and 2DG in
LNCaP cells under normoxia or hypoxia inhibited proliferation to a greater extent than either compound alone. These results suggest
that the antiangiogenic and microtubule disruption activities of STX140 may make tumours more susceptible to inhibition of glycolysis
by 2DG. This is the first study to show the benefit of combining a microtubule disruptor with 2DG in the two most common solid
tumours.
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A majority of both breast and prostate tumours initially present as
hormone-dependent diseases and hormone deprivation therapy is
efficacious. However, a significant number of these tumours will
become hormone-independent and require more aggressive treat-
ments. Current treatments for advanced breast and prostate cancer
are limited, with resistance and toxicity being common problems
with many therapies (Gottesman et al, 2002). Solid tumours are
particularly difficult to treat because conventional chemotherapeutic
drugs and radiation therapy only target the rapidly growing
peripheral cells, leaving the slower proliferating tumour cells in
the hypoxic core to survive (Brown and Giaccia, 1998).
Normal healthy cells undergo aerobic respiration to produce
ATP; however, Warburg showed that, even in the presence of
oxygen, cancer cells create ATP anaerobically, relying on
glycolysis, the Warburg effect (Warburg and Dickens, 1930).
Hence, inhibiting glycolysis could specifically target cancer cells
without having deleterious effects on normal cells. Glycolysis is
inhibited by using the glucose analogue, 2-deoxy-D-glucose (2DG),
where the C-2 hydroxy group of glucose is replaced by a hydrogen
(Figure 1, A and B). Both glucose and 2DG are phosphorylated by
hexokinase; however, in contrast to glucose 6-phosphate, 2DG 6-
phosphate cannot be further metabolised to fructose-6-phosphate
by phosphoglucose isomerase (Nirenberg and Hogg, 1958). In
addition to blocking the glycolytic pathway, 2DG competes with
glucose for uptake by the hexose (GLUT) transporters (Wachs-
berger et al, 2002), thus limiting the uptake of glucose by the cell.
Several studies have shown the antitumour activity of 2DG alone
in vitro and in vivo (Kaplan et al, 1990; Liu et al, 2001; Aft et al,
2002; Maschek et al, 2004; Gupta et al, 2005; Lampidis et al, 2006).
However, very few clinical studies have tested 2DG as a single-
agent therapy and the results of such studies have been
disappointing (Landau et al, 1958; Kaplan et al, 1990). Combining
2DG with other anticancer modalities, such as chemotherapy or
radiotherapy, could improve the efficacy of anti-glycolysis-based
therapy (Singh et al, 2005; Simons et al, 2007). Maschek et al
(2004) hypothesised that chemotherapy may kill the rapidly
growing cells as 2DG targets the slowly proliferating inner core
of cells, which are more reliant on glycolysis. This hypothesis was
supported by the observation that a combination of 2DG and the
anthracycline, adriamycin, was significantly more efficacious than
either agent alone in an osteosarcoma xenograft model. Pre-
liminary studies by the same group, in a NSCLC xenograft model,
also indicated a possible benefit of combining paclitaxel and 2DG
(Maschek et al, 2004).
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s2-Methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140) is an
orally bioavailable microtubule disruptor that can be dosed daily
in vivo, with little blood toxicity being observed (Ireson et al, 2004;
Newman et al, 2007; Foster et al, 2008c). Microtubule disruption
by STX140 leads to cell cycle arrest and subsequent apoptosis of
both tumour and endothelial cells (Foster et al, 2008a). The
proliferation of both breast, MCF-7 (ER-positive), cells (Newman
et al, 2004) and prostate, LNCaP (AR-positive), cells (Day et al,
2003) is inhibited in vitro by STX140. Furthermore, STX140
inhibits both in vitro angiogenesis (Newman et al, 2004) and in
vivo angiogenesis (Chander et al, 2007).
A potential strategy for treating solid tumours would be to
combine an antiangiogenic–microtubule disruptor, STX140, with
an inhibitor of glycolysis, 2DG. The inhibition of angiogenesis by
STX140 may increase hypoxia and thus make the tumour even
more reliant on glycolysis, in theory sensitising the tumour further
to 2DG.
The efficacy of combining 2DG with a new-generation micro-
tubule disruptor, STX140, in xenograft models of the most
common solid tumours in women and men is reported for the
first time in this study.
MATERIALS AND METHODS
Compounds
2-Deoxy-D-glucose (Figure 1, B) was obtained from Sigma (Poole,
UK). 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate (Figure 1, C)
was synthesised as described previously (Leese et al, 2006).
2-Methoxyoestradiol-3,17-O,O-bis-sulphamate yielded spectro-
scopic and analytical data in accordance with its structure.
Cell culture
MCF-7 and LNCaP cells were obtained from the American Tissue
Culture Collection (LGC Promochem, Teddington, UK). Cells were
cultured in the following medium obtained from Sigma: RPMI
1640 with 10% foetal bovine serum, 1% L-glutamine, 1% MEM
non-essential amino acids and 1% sodium bicarbonate solution.
LNCaP cells also required 1% sodium pyruvate. Cells were
maintained in a humidified incubator at 371C under 5% CO2.
For hypoxic experiments an Innova CO-48 CO2 humidified
incubator (Newbrunswick Scientific, St Albans, UK) was used,
oxygen was maintained at 1% and CO2 at 5% in a humidified
atmosphere at 371C.
Proliferation assay
MCF-7 and LNCaP cells were seeded at 3000 and 5000cells per well,
respectively, in 96-well plates. To ensure that cells had adhered to
the plate, compounds were not added until 4h after the seeding of
the cells. After 72–96h cell numbers were measured by the addition
of 10ml of Alamar blue (Biosource, Nivelles, Belgium) for 2h and,
subsequently, fluorescence was quantified using a FluoStar Optima
(BMG Labtech, Offenburg, Germany) Plate reader (544nm excita-
tion; 590nm emission).
Measurement of ATP
MCF-7 and LNCaP cells were seeded at 3000 and 5000cells per
well, respectively, in 96-well plates. Compounds were added 4h
after seeding of cells. The ATPlite assay procedure was carried out
according to the manufacturer’s instructions (Perkin-Elmer,
Beaconsfield, UK). The luminescence emitted from the ATP-
dependent luciferase reaction was measured using a FluoStar
Optima Plate reader.
Cell cycle/apoptosis analysis
Cells were plated in T-25 flasks so that after 24h they were 60–70%
confluent and were then treated with the compounds for a further
48h. Control cells were untreated or treated with tetrahydrofuran
(THF) vehicle only. To harvest cells for flow cytometric DNA
analysis, cells were washed with PBS before being trypsinised
(0.25% trypsin, 0.05% EDTA). The medium containing non-
adherent cells was also collected and pooled with the trypsinised
cells. The cells and PBS-washings were pelleted by centrifugation at
1500rpm and washed twice with PBS.
For cell cycle analysis the cells were then fixed in cold 70%
ethanol, treated with 100mgml
 1 RNase for 5min, stained with
50mgml
 1 propidium iodide and analysed using a flow cytometer
(FACScan, Becton Dickinson, Cowley, UK).
For quantification of apoptosis the cells were re-suspended
in binding buffer (10mM HEPES/NaOH pH 7.4, 140mM NaCl,
2.5mM CaCl2)a t1  10
6cellsml
 1. Cells were then stained with
fluorescein-conjugated Annexin V (BD Biosciences, Cowley, UK)
antibody and propidium iodide (5mgml
 1) before flow cytometric
analysis. Apoptotic cells are defined as cells positive for Annexin V
and negative for propidium iodide.
In vivo tumour xenograft model
Intact, athymic, female and male MF-1 nude mice (nu /nu ) were
purchased from Harlan (Bicester, Oxon, UK) at 5 weeks of age
(B20–25g in weight). All efforts were made to minimise both
suffering and the number of animals used. Experiments were
carried out under the UK Animals (Scientific Procedures) Act 1986
and complied with institutional guidelines. Animals were kept in a
12h light/12h dark cycle and given food and water ad libitum.
Five million cells (MCF-7 or LNCaP), in ice-cold Matrigel
(BD Biosciences), were inoculated s.c. into the right flank of the
animals. Once the tumours reached 100–150mm
3 in volume, mice
were randomly divided into four treatment groups (n¼5):
(1) Vehicle (10% THF; 90% propylene glycol (PG)), 100ml p.o.
(oral gavage) þ saline i.p. 200ml.
(2) Vehicle p.o. þ 2DG (2gkg
 1) i.p. 200ml.
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Figure 1 Structures of glucose (A) and 2DG (B). Glucose and 2DG
differ at the second carbon. Chemical structure of STX140 (C).
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s(3) STX140(5mgkg
 1)1 0 0ml p.o. þ saline i.p. 200ml.
(4) STX140 (5mgkg
 1) p.o. þ 2DG (2gkg
 1) i.p. 200ml.
All treatments were administered daily for 4 weeks. Throughout
the study mice were weighed and tumour measurements were
taken on a weekly basis with electronic calipers. The dose of 2DG
used was based on the work of Maschek et al (2004); STX140 was
used at a quarter (5mgkg
 1 p.o.) of its optimal dose (20mgkg
 1
p.o.); hence, any additive effect with 2DG could easily be observed
(Foster et al, 2008b). Tumour volumes were calculated using
the formula length width
2/2. At the end of the study,
MCF-7 tumours were placed in 10% formalin solution (Sigma)
for immunohistochemical (IHC) analysis.
Immunohistochemistry
von Willebrand’s factor IHC analysis was performed on paraffin-
embedded MCF-7 tumour sections cut at 6mm. After sectioning,
rehydration and antigen retrieval steps, von Willebrand’s antibody
(1:800, Abcam, Cambridge, UK) was applied to the section for 1h
at RT, followed by a goat polyclonal secondary antibody
conjugated to FITC (30min at RT). In addition, sections were
cut for routine H&E staining. Sections were viewed with a Zeiss
Axiovert 200 fluorescence microscope (Carl Zeiss Ltd, Welwyn
Garden City, UK) fitted with 20  and 40  Plan-Neofluor
objectives. Images were captured using the Axiovision imaging
system (Imaging Associates, Bicester, UK).
Statistics
All experiments were carried out in triplicate and data presented
are representative of one of three such experiments, unless
indicated. All errors shown are the mean±s.e.m., unless otherwise
stated. Student’s t-test was used to assess the significance of the
differences in cell proliferation, ATP levels in vitro and changes in
tumour volume in vivo.
RESULTS
Inhibition of proliferation by 2DG
The ability of 2DG to inhibit the proliferation of MCF-7 and LNCaP
cell lines was examined over a 96-h period under normoxic
conditions (Figure 2A). The results show a reduction in MCF-7 and
LNCaP cell proliferation with increasing 2DG concentration. The
potency of 2DG was similar in both cell lines (MCF-7, IC50: 8.1mM
and LNCaP, IC50: 6.7mM). The difference in IC50 values between
MCF-7 and LNCaP cells was not significant. Based on these
findings, 8mM 2DG was used for all further proliferation studies,
as this is the approximate IC50 value for both cell lines.
Effect of 2DG and hypoxia on ATP levels
To measure ATP concentrations cells were exposed to a non-cytotoxic
dose (3mM for 72h, data not shown) of 2DG either in normoxia or in
hypoxia, to ensure that any changes in ATP levels measured were a
result of the inhibition of glycolysis and not because of a reduction in
cell number (Figure 2B and C). LNCaP cells were more sensitive to
hypoxia, with a greater reduction in ATP levels observed both in the
presence and in the absence of 2DG in comparison to the MCF-7 cells
( 2DG, 9.0mM±2.1 vs 2.9mM±2.2 SD, Po0.05; þ2DG, 5.7mM±1.5
vs 3mM±0.4 SD, Po0 . 0 5 ) .I nc o n t r a s t ,as i m i l a rr e d u c t i o ni nA T P
levels (8.8–12.6mM) was observed by the addition of 2DG to both cell
types in either normoxia or hypoxia. The combination of hypoxia and
2DG reduced ATP levels to 5.1mM in the MCF-7 cells and to 3.7mM
in the LNCaP cells, a reduction of 75% (***Po0.001) and 83%
(***Po0.001) vs untreated, respectively.
Inhibition of proliferation by 2DG and STX140
The growth-inhibitory effects of 2DG and STX140, used alone and
in combination, were compared in MCF-7 and LNCaP cells, under
both normoxia and hypoxia in vitro (Figure 3A and B). The growth
inhibition was determined after 72h. Compared with normoxic
untreated controls, STX140 (0.5mM) inhibited cell proliferation by
45 and 48% in MCF-7 cells (Po0.01, Figure 3A) under normoxia
and hypoxia, respectively, and by 65% in LNCaP cells (Po0.001,
Figure 3B) under both normoxia and hypoxia. Under normoxic
conditions, in both cell types, 2DG alone (8mM) inhibited cell
proliferation by 50%. Under hypoxic conditions 2DG inhibited cell
proliferation by 70 and 75% in MCF-7 and LNCaP cells,
respectively, a significant increase in efficacy relative to normoxic
conditions (Po0.01). Compared with STX140 at 0.5mM, 2DG
(8mM) alone is significantly more effective at inhibiting tumour
cell proliferation in both cell types (MCF-7: Po0.01 and LNCaP:
Po0.05) under hypoxia, but not under normoxia (Figure 3A and
B). The addition of STX140 (0.1–0.5mM) did not further enhance
the inhibition of cell proliferation seen with 8mM 2DG in MCF-7
cells either in normoxia or in hypoxia (Figure 3A). However,
improved efficacy was seen when combining the two agents in
vitro in the LNCaP cells. The combination of 0.1mM STX140 and
8m M 2DG was more potent (*Po0.05) than either compound
alone under normoxia at these concentrations. In contrast, this
result was not seen under hypoxic conditions with the same
concentrations. However, 8mM 2DG plus either 0.5 or 1.0mM
STX140 was more potent (*Po0.05 and **Po0.01, respectively)
than either compound alone under hypoxia at these concentra-
tions; this result was not seen under normoxia with the same
concentrations.
Cell cycle/apoptosis
To understand the possible mechanisms for STX140/2DG-
mediated cell death, both the cell cycle state and mechanism of
cell death were assessed by FACS analysis (Figure 4A and B).
Earlier studies showed that STX140 induced cell cycle arrest and
apoptosis in a range of tumour cell lines (Day et al, 2003;
Raobaikady et al, 2005; Newman et al, 2007). In both cell types
2DG alone in normoxia had little effect compared with untreated
controls, although a reduction in the S-phase population was seen
in LNCaP cells (
DDDPo0.001). In LNCaP cells under hypoxia, 2DG
alone significantly (
&Po0.05) reduced the number of cells in G1
and G2/M compared with normoxic and hypoxic controls and with
2DG alone in normoxia. Despite this, no significant increase in
cells undergoing apoptosis was detected. In MCF-7 cells under
hypoxia a small increase was seen in the G2/M and apoptotic cell
population compared with normoxia alone (
’’Po0.01). Similar
data were seen for STX140 in hypoxia compared with STX140 in
normoxia in MCF-7 cells (
þþþPo0.001). However, 2DG had little
effect in MCF-7 cells under hypoxia and the extent of apoptosis
measured was the same as seen for hypoxia alone.
In the LNCaP cell line STX140 alone and STX140 with 2DG
under hypoxia induced the greatest extent of apoptosis seen in this
study; approximately 20% of cells were undergoing apoptosis
(**Po0.01). In contrast, the greatest extent of apoptosis observed
in the MCF-7 line was only 10%, and the combination of hypoxia,
2DG and STX140 was less effective (
KKPo0.01) than STX140
alone in hypoxia and 2DG combined with STX140 in normoxia
(
~~~Po0.001 vs normoxia control).
Effect of STX140 and 2DG in vivo
As no previous studies have investigated in vivo the combination
of a microtubule disruptor and 2DG in breast and prostate cancer,
the efficacy of STX140 and 2DG was assessed in the MCF-7 (ER-
positive, breast) and LNCaP (AR-positive, prostate) xenograft
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smodels. In the breast cancer model (MCF-7) at the end of dosing
(day 42), vehicle-treated tumours had increased in size by
1165±75% relative to the tumour starting volumes on day 14.
Growth of MCF-7 tumours was significantly inhibited by STX140
(5mgkg
 1 p.o.; daily), tumours having increased in size by
664±135% (Po0.05). In mice treated with the combination of
STX140 (5mgkg
 1 p.o.; daily) and 2DG (2gkg
 1 i.p.; daily)
tumours increased in size only by 328±82% (Po0.001). The inset
figure reveals that no weight loss occurred, indicating the potential
absence of toxicity with these treatments (Figure 5A).
Figure 5B shows representative sections cut from the MCF-7
xenografts stained with an endothelial specific marker, von
Willebrand’s factor, to assess vessel density. 2-Methoxyoestra-
diol-3,17-O,O-bis-sulphamate (5mgkg
 1 p.o.; daily) and STX140
(5mgkg
 1 p.o.; daily) combined with 2DG (2gkg
 1 i.p.; daily)
caused a reduction in the staining for endothelial cells (indicated
by arrows). 2-Deoxy-D-glucose (2gkg
 1 i.p.; daily) alone had no
effect (data not shown). Conventional H&E staining revealed that
the reduction in von Willebrand’s staining is not because of a
decrease in cell density (Figure 5C).
In the prostate cancer model (LNCaP) at the end of dosing (day
28), vehicle-treated tumours had increased in size by 614±162%
relative to the tumour starting volumes on day 0. The combination
of STX140 (5mgkg
 1 p.o.; daily) with 2DG (2gkg
 1 i.p.; daily)
significantly (Po0.001) inhibited tumour growth compared with
STX140 alone. No weight loss occurred, indicating the absence of
toxicity with these treatments (data not shown) (Figure 6).
DISCUSSION
Liu et al (2001) recently proposed that 2DG combined with a
traditional chemotherapeutic agent may offer a new strategy for
cancer therapy. They hypothesised that 2DG would target the
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Figure 3 Effects of 2DG and STX140 on the proliferation of MCF-7 (A) and LNCaP (B) cells. Cells were cultured in 96-well plates, under normoxia or
hypoxia, and treated with 2DG (8mM) and/or STX140 (0.1–1mM) for 72h when their effects on proliferation were measured by using a microtitre plate
assay. Results are expressed as percent of proliferation of untreated cells in normoxia. In both cell lines 2DG alone was significantly (Po0.001) more potent
in hypoxia vs normoxia. There was no significant benefit of 2DGþSTX140 in MCF-7 cells. In LNCaP cells under normoxia, 2DGþ0.1mM STX140 gave
significantly greater inhibition than 2DG alone (*Po0.05) and 0.1mM STX140 alone (Po0.001). Under hypoxia, 2DGþ0.5mM STX140 and 2DGþ1.0mM
STX140 gave significantly greater inhibition than 2DG alone (*Po0.05 and **Po0.01) and 0.5 and 1.0mM STX140 alone (Po0.001) (ns¼not significant vs
untreated normoxia).
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Figure 2 (A) Effect of 2DG on the proliferation of LNCaP and MCF-7 cells. Cells were cultured in 96-well plates and treated with 2DG (0.005–50mM)
for 96h when their effects on proliferation were measured using a microtitre plate assay. Effect of 2DG and hypoxia on ATP levels in MCF-7 (B) and LNCaP
cells (C). Cells were cultured in 96-well plates under normoxia and treated with 2DG (3mM) for 72h when their effects on ATP were measured using the
microtitre, ATPlite plate assay. Results are expressed as percent of untreated. At this dose of 2DG, no significant inhibition of cell proliferation occurred (data
not shown).
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sslowly proliferating cells at the hypoxic centre of the tumour,
which are highly dependent on glycolysis, and a chemotherapeutic
agent would target the rapidly proliferating cells towards the
tumour rim. In our study the combination of STX140 with 2DG
was a potent inhibitor of tumour growth, in both breast and
prostate cancer xenograft models in vivo. The excellent efficacy of
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Figure 5 (A) Growth of MCF-7 tumours in athymic nude mice. Growth of MCF-7 tumours was inhibited by STX140 (5mgkg
 1 p.o.; daily) (*Po0.05)
and STX140 (5mgkg
 1 p.o.; daily) þ 2DG (2gkg
 1 i.p.; daily) (***Po0.001) after 28 days dosing relative to control. There was no effect on mouse weight
throughout the study (inset), indicating a potential lack of compound toxicity. Points, mean percentage change in tumour volume; bars, s.e.m. (B) von
Willebrand’s factor staining of tumour sections. Administration of STX140 (5mgkg
 1 p.o.; daily) or STX140 (5mgkg
 1 p.o.; daily) þ 2DG (2gkg
 1 i.p.;
daily) caused a decrease in blood vessels relative to tumours taken from untreated animals. (C) H&E staining of tumour sections. No decrease in overall cell
number was observed by H&E staining. Scale bar¼100mM, magnification 200.
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apoptosis the cells were re-suspended in binding buffer and then stained with fluorescein-conjugated Annexin V antibody and propidium iodide before flow
cytometric analysis. Apoptotic cells are defined as cells positive for Annexin V and negative for propidium iodide. All treatments lasted for 48h (
DDDPo0.001
vs normoxia control;
&Po0.05 vs normoxia control, hypoxia control and 2DG alone in normoxia;
’’Po0.01 vs normoxia control;
þþþPo0.001 vs
normoxia STX140; **Po0.01 vs normoxia and hypoxia control;
KKPo0.01 vs STX140 in hypoxia 2DG combined with STX140 under normoxia;
~~~Po0.001 vs normoxia control; and ns¼not significant).
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Liu et al.
In this study 2DG was combined with STX140, a microtubule
disruptor. To date, only one limited study has combined a
microtubule disruptor with 2DG. In a NSCLC xenograft model,
the combination of 2DG and paclitaxel showed some efficacy
(Maschek et al, 2004). However, paclitaxel was administered i.p.,
which was not the optimal route, and no data were shown for the
effect of 2DG alone. Furthermore, taxanes may not be the best
partner for 2DG, as 2DG induces P-glycoprotein expression, which
can expel the taxanes from the cell, leading to a multi-drug-resistant
phenotype in the clinic (Ledoux et al, 2003; Fojo and Menefee,
2005). In contrast to the taxanes, STX140 is not a substrate for P-
glycoprotein and is highly efficacious both in vitro and in vivo in
cells overexpressing P-glycoprotein (Newman et al,2 0 0 8 ) .
In the MCF-7 breast xenograft model the combination of
STX140 and 2DG inhibited tumour growth to the greatest extent;
2DG alone did not have any significant effect on tumour growth.
Staining of tumour sections for the endothelial specific marker,
von Willebrand’s factor, showed a decrease in blood vessel density
in response to STX140 alone and the combination of STX140 and
2DG. The decrease in blood vessel density observed agrees with
previous studies, which showed a significant reduction in blood
vessel density in both the MCF-7 and MDA-MB-231 xenograft
models in response to STX140 (Chander et al, 2007; Foster et al,
2008a). Further work needs to be undertaken to see if the STX140-
mediated reduction in blood vessel density increases intratumoral
hypoxia, leading to an increased reliance on glycolysis and thus
sensitising the cancer cells further to 2DG. In this study, and the
studies of Chander et al (2007) and Foster et al (2008a), daily
dosing with STX140 did not cause significant weight loss and there
were no gross signs of damage to the normal vasculature,
indicating that the efficacious dose of STX140 lacks toxicity.
To test the applicability of this initial in vivo finding, STX140
combined with 2DG was tested in an in vivo model of prostate
cancer, one of the most common cancers in man. In confirmation
with the previous data, STX140 and 2DG significantly inhibited
LNCaP tumour growth compared with STX140 alone. Mono-
therapy with 2DG had no significant effect on tumour growth.
Unlike the MCF-7 model, no efficacy was seen with STX140 alone,
further highlighting the benefit of combining the two agents.
Although some studies do report weight loss in response to 2DG
(Maschek et al, 2004), our data, in both models, concur with
those of Gupta et al (2005), who reported no weight loss in
response to 2DG.
The dose of STX140 used in these combination studies was
approximately a quarter of the optimal dose so far identified
(Foster et al, 2008b), and as such, more work needs to be
undertaken to optimise the dosing of this combination treatment.
Furthermore, this work indicates that the addition of 2DG to a
chemotherapeutic regime may allow for lower doses of chemother-
apy to be used, thereby reducing chemotherapy-related toxicity.
To investigate how the combination of 2DG and STX140 may
target tumour cells, a series of in vitro experiments were
undertaken; in these studies a hypoxic incubator was used to try
and model the inner core of the tumour. The MCF-7 and LNCaP
cell lines were equally sensitive to 2DG alone in vitro, with
approximate IC50 values of 8mM being obtained for both cell lines
in normoxia. This value is in agreement with other studies that
have shown IC50 values in the range of 4–12mMin a variety of cell
lines (Kaplan et al, 1990; Aft et al, 2002; Lampidis et al, 2006). The
relatively high IC50 values for the inhibition of proliferation reflect
the fact that 2DG has to compete with glucose in the culture
medium for uptake into the cells. When the cells were grown under
hypoxic conditions their sensitivity to 2DG significantly increased.
These data suggest that under hypoxia the cells become more
reliant on glycolysis and are therefore more sensitive to 2DG. This
is supported by the significant reduction in cellular ATP levels
seen in response to hypoxia alone, and the further reduction in
ATP levels observed when hypoxia is combined with 2DG. Even in
normoxia both these cell lines appear to be reliant on glycolysis to
some extent, as 2DG alone in normoxia reduces ATP production
by over 50% compared with normoxic controls. The combination
of STX140 with 2DG only enhanced the inhibition of cell
proliferation seen with 2DG alone, in the LNCaP cell line, at low
doses of STX140 in normoxia and only at higher doses of STX140
in hypoxia. This result was supported by the significant increase in
apoptosis seen with STX140 and 2DG under hypoxia compared
with other treatments in the LNCaP cells, but not in the MCF-7
cells. These in vitro data further support the hypothesis of Liu et al.
(2001), as the chemotherapeutic agent, STX140, is equally
efficacious in normoxia and hypoxia but 2DG is more efficacious
in the hypoxic environment, which is hypothesised to reflect the
centre of the tumour.
This study for the first time shows the benefit of combining 2DG
with an antiproliferative compound in vivo in the two most
common cancers. This work supports the continued investigation
into the use of 2DG combined with chemotherapeutic drugs for the
treatment of cancer.
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